C4 Therapeutics, Inc.

We welcomed students from the Ewha Womans University in Korea through its “Pharm Challenger Project” – an opportunity for students to visit organizations researching new areas of medicine. For their project, these women are eagerly exploring the world of targeted protein degradation, researching the current state of the field and its potential to impact patients. Our team had a fantastic day with the students, guiding them through our #TPD approach and mission to create a new way to treat diseases like cancer. As we celebrate International Day of Women and Girls in Science, hear from our vice president of clinical pharmacology, Eunju Hurh, about the impact of helping young scientists learn more about the many different areas of therapeutic development. #February11 #WomenInScience #IDWGS

Transforming a patient’s treatment experience is one of the driving factors of our work to create a new generation of #TPD medicines. Treatment resistance is a defining challenge in our disease areas of focus, including multiple myeloma and BRAF V600 mutant cancers. Learn about our approach to treating cancer by degrading disease-causing proteins to potentially prevent new mutations that cause treatment resistance. https://bit.ly/3Q1804k #WorldCancerDay #cancerresearch #cancer #myeloma #lymphoma #CRC #melanoma

Have you visited our Scientific Presentations & Publications page? Check it out to view past presentations from industry events and learn about progress across our discovery platform and clinical programs: https://bit.ly/405hAYS #TPD #biotech

Learn about cancers with BRAF mutations – the target of our CFT1946 program, an orally bioavailable BiDAC™ degrader of BRAF V600 mutations. CFT1946 is currently being studied in a Phase 1/2 clinical trial in patients with BRAF V600 mutant solid tumors. BRAF V600 mutations are found in cancers including melanoma and colorectal cancer (CRC). Visit our website for more: https://bit.ly/43ygxPi

Martin Luther King Jr.’s message of having integrity and empathy for others is a reminder of why we contribute to our community, support our colleagues and are driven to develop medicines that transform lives. #MLKDay

The spark that ignited the field of #TPD began in 1999 with a realization that disease-causing proteins could be tagged by E3 ligases and destroyed by the proteasome. Since then, clinical progress has opened a new path for targeting previously undruggable proteins driving cancer, inflammation, and neurodegeneration. Check out this article in Chemistry World for a detailed history on our field, including insights from our chief scientific officer Paige Mahaney on the vast potential for new TPD treatments to transform patients’ lives.

We announced anticipated milestones for 2025 as we advance our clinical portfolio of orally bioavailable #degrader medicines targeting cancers with high unmet needs. Read more in our latest press release: https://bit.ly/3DNnNzJ #TPD

We will present at the J.P. Morgan 43rd Annual Healthcare Conference on Wednesday, January 15 at 2:15 p.m. PST in San Francisco. Learn more in our latest release: https://bit.ly/4gH713S #TPD #biotech #JPM25

Our annual holiday shutdown begins soon, an opportunity to reflect on the impactful and momentous year we’ve had and refresh ourselves for all that is to come in the new year. Wishing the #C4TxTeam, our partners and community a happy holiday – we’ll see you in 2025!

2024 was a transformative year for the #C4Txteam, one that elevated our discovery and clinical initiatives, welcomed new leaders to guide our progress and heightened our momentum to deliver transformative progress through targeted protein degradation (#TPD) science. Along the way we launched a new discovery partnership with Merck KGaA, Darmstadt, Germany, saw our CFT8919 program reach the clinic alongside Betta Pharmaceuticals Co., Ltd. , shared findings from our cemsidomide and CFT1946 clinical trials, were recognized by the BostInno Fire Awards and Boston Globe Media's Top Places to Work and so much more. We’re thrilled to see all that’s to come in the new year!